Regulation of iron balance in humans.
Long term follow up of older patient with iron
deficiency anemia after negative GI evaluation.
Laboratory diagnosis of iron deficiency anemia.
Use of recombinant human erythropoeitin outside the
setting of uremia.
Intravenous iron and erythropoeitin for anemia
associated with crohn’s disease.
Erythropoeitin therapy.
Clinical experience of management of thalassemia.
Long term trial of deferiprone in transfusion
dependent iron over loaded patients.
Bone marrow transplantation in adult thalssemia
patients.
Management of sickle disease.
Longterm safety and effectiveness of iron chelation
therapy with deferiprone for thalassemia major.
Screening for vitamin B-12 deficiency – underdiagnosed,over treatment.
Auto antibodies against erythropoetin in a patient
with pure red cell aplasia.
The pathophysiology of pure red cell
aplasia,indications for therapy associated with large granular lymphocyte
leukemia and the prognostic value of cytogenetic abnormalities.
Red cell abnormalities in hereditary spherocytosis
– prevalence of diagnosis and understanding of the variable expression of
clinical severity.
Hereditary spherocytosis with spectrin deficiency due
to an unstable truncated beta spectrin.
Pathogenesis and treatment of sickle cell disease.
Collaborative multicentre investigation of marrow
transplantation for sickle cell disease.
Risks in sickle cell traits.
Transfusion therapy in autoimmune hemolytic anemia.
Microangiopathic hemolytic anemia complicating FK
506(tacrolimus)therapy.
Long term outcome after marrow transplantation for
severe aplastic anemia.
Effectiveness of immunosuppressive therapy in older
patients with aplastic anemia.
The out patient management of febrile neutropenia in
cancer patients.
Pathophysiology and treatment of severe chronic neutropenia.
Un related donor bone marrow transplantation for
chronic myelogenous leukemia.
International scoring system for evaluating prognosis
in myelodysplastic syndromes.
Importance of diagnostic cytogenetics on outcome in
AML.
Acute lymphoblastic leukemia.
Hemolytic anemia after fludarabine therapy for
chronic lymphocytic leukemia.
New approach to classifying non-hodgkin’s lymphoma
– clinical features of the major histologic subtypes.
The international prognostic index co relates to
survival in patients with aggressive lymphoma in relapse.
Prognostic score for advanced hodgkin’s disease.
Drug induced thrombocytopenia.
Pathophysiology & management of thrombotic
thrombocytopenic purpura.
Adult hemolytic uremic syndrome.
Hemophilia – diagnosis,comprehensive care and
assessment.
Hemostatic drugs.
Platelet function defects associated with hemorrhage
or thrombosis.
Treatment of inherited coagulation disorders.
Successful treatment of acquired hemophilia with oral
immunosuppressive therapy.
Thrombopoetin levels in patients with cirrhosis
before and after orthotopic liver transplantation.
Stimulation of megakaryocyte and platelet production
by a single dose of recombinant human thrombopoetin in patient with cancer.
Disseminated intravascular coagulation – objective
clinical & laboratory diagnosis,treatment & assessment of therapeutic
response.
Management of venous thrombo embolism.
Hypercoagulability in venous and arterial thrombosis.
Clinical outcomes after transfusion associated
hepatitis-C.
Transfusion medicine.
A restrictive platelet transfusion policy allowing
long term support of out patients with severe aplastic anemia.
Management of thrombosis in the anti phospholipids
– antibody syndrome.